Kornimate/medical-research-clean huggingface dataset:
radiostereometric analysis of spine arthrodesis

Conditions: Lumbar Degenerative Disc Disease

Summary: the primary objective of this pilot study is to determine the precision of post-operative radiostereometric measurements for the assessment of lumbar spinal fusion. this study will also determine the potential for rsa as a more precise and accurate means for assessment of lumbar spinal fusion and diagnosis of pseudarthrosis.


Eligibility criteria:
inclusion criteria: * symptomatic degenerative disc disease of the lumbar spine indication surgical intervention * scheduled to undergo lumbar fusion surgery * patients between the ages of 18 and 75 * ability to give informed consent exclusion criteria: * pregnant women
swept source oct imaging with the dream vg-oct

Conditions: Eye Diseases; Myopia; Glaucoma

Summary: the intalight dream oct is the first combo anterior plus posterior device to perform both oct and oct-a at depth of 16mm. this is especially useful in patient who are very nearsighted as it allows us to image all in one frame. the intention of this study is to see how the images differ on the same patients when compared to the cirrus oct and to test for the repeatability of the images on a single day.


Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 * myopes with a current or previously documented spherical equivalent refraction \< -4d * at least half of the subjects should have had at least one cirrus oct rnfl and macula performed as well as a humphrey visual field performed in those with oct abnormalities exclusion criteria: * unable to comply with study imaging * unclear ocular media * participant has, in the opinion of the investigator, any physical or mental condition that would affect the participation in the study or may interfere with the study procedures, evaluations and outcome assessments.
fatigue, quality of life, cognitive function and physical ability in patients suspected of colorectal malignancy

Conditions: Iron-deficiency; Iron Deficiency Anemia; Colorectal Cancer; Fatigue; Quality of Life; Cognitive Impairment

Summary: the aim is to investigate if iron deficiency at the time of colorectal cancer diagnosis has an influence on fatigue, quality of life, cognition and physical ability.

around 60% of newly diagnosed colorectal cancer patients suffer from iron deficiency at the time of diagnosis. the study hypothesis is that, besides leading to anemia, iron deficiency might be associated with impaired patient report outcomes in the domains of fatigue, quality of life, cognitive impairment and lower physical ability. no previous studies on colorectal cancer patients and iron deficiency are available. the participants (patients suspected of colorectal cancer after endoscopy) will be tested on these parameters. the participants and the investigators are blinded to the patients iron status. the study takes place before any preoperative iron treatment. multivariate analysis will be used taking into account, gender, age, hemoglobin, tumor stage.

Eligibility criteria:
inclusion criteria: * patients in whom endoscopy has raised suspicion of colorectal malignancy exclusion criteria: * non fluent in danish language * cerebral impairment (ex severe dementia) so that informed consent can not be obtained
re³ (re-cube: retain remicade® response)(study p04249am3)

Conditions: Rheumatoid Arthritis

Summary: this phase iiib, randomized, multi-national, multi-center, blinded study of infliximab (ifx) in subjects aged 18 and older with active ra is being conducted to assess whether increasing either the infusion dose or infusion frequency in patients presenting with a disease flare after an initial response to infliximab results in a significant improvement in disease activity. subjects responding to an initial infliximab treatment regimen, who flare during continuation of treatment at 3 mg/kg administered every 8 weeks, will be randomly assigned to one of 3 different dosing regimens of infliximab and will be treated for 4 or 5 consecutive infusions for a total duration of 24 weeks. the infliximab control group and the infliximab increased dose group are evaluator and subject-blinded. the increased frequency group is not blinded. clinical assessments of disease activity will be based the european league against rheumatism (eular) criteria for response. safety parameters will be assessed at every infusion. a disease flare is defined by an increase in das28 with 0.6 or more at screening, when compared to the das28 score measured immediately prior to the last remicade® infusion and depends upon the actual score as well. since prior to enrollment, the subject received remicade® as per routine clinical practice, the days on which infusions were administered and assessments are done during the induction period do not have to be exactly at week 2, 6 and 14. * drug: infliximab control (double-blinded) * drug: infliximab increased dose (double-blinded) * drug: infliximab increased frequency (open-label)


Eligibility criteria:
inclusion criteria: * aged 18 years or more * with ra according to acr criteria * presented with a disease flare after initial response to infliximab, with both response and flare being defined using the das28 score (eular criteria) * received the standard remicade® dosing schedule per the eu label (3 mg/kg at weeks 0, 2, 6, \[and 14\]) * an initial response documented by moderate or good das28 improvement (eular criteria) from week 0 to week 6 or 14. exclusion criteria: * a female who is, or intends to become, pregnant during or within 6 months of the end of the study, is nursing or not using adequate contraceptive measures * has not observed the designated periods for concomitant medications * used any investigational medical product within 30 days prior to baseline * any clinically significant deviation from normal in the physical examination or chest x-ray that in the investigator's judgment, may interfere with the study evaluation or affect subject safety * rheumatic disease other than ra or has any systemic inflammatory condition with signs and symptoms that might confound the evaluations of safety and toxicity * allergic reaction/sensitivity to the study drug or its excipients that requires corticosteroid pre-infusion medication.
effect of apples on cardiovascular risk and gut health

Conditions: Mild Hypercholesterolemia

Summary: there is now considerable scientific evidence that a diet rich in fruits and vegetables could improve human health. apples are among the most frequently consumed fruits in the world. epidemiological studies have linked frequent apple consumption with several health benefits including a reduced risk of cardiovascular disease. apples are an important source of polyphenols and fiber and their beneficial effects could be attributed to this content; however, their impact on our health is not clear. although, there are some studies that have reported cholesterol lowering effects the results are inconsistent. furthermore, few studies have explored the impact on vascular function and gut microbiota. the objective of the current study is to assess whether a regular apple consumption, reduces total cholesterol levels, improves vascular function and gut microbiota profile in mildly hypercholesterolemic subjects compared with a control, sugar matched commercial clear apple juice squash.


Eligibility criteria:
inclusion criteria: * mildly hypercholesterolemic: tc\>5.2 and \<7.9 mmol/l * bmi: 20-35 * age: 23-69 * normal liver and kidney function exclusion criteria: * drug treatment for hyperlipidaemia, hypertension, inflammation and hypercoagulation. * vegetarians. * smoking. * history of alcohol misuse. * history of food allergy (e.g. apples, sulphites). * taking antibiotics for the previous 3 months. * taking phytochemical, antioxidant, fish oil supplements, or prebiotic/probiotic preparations unless willing to stop for the study period and after a 4 week wash out period (8 weeks for fish oil). * females who are pregnant, lactating, or if of reproductive age and not using a reliable form of contraception (including abstinence). * medical history of cardiovascular disease including coronary heart disease (angina and heart attack) and stroke (in the past 12 months). * family history of cardiovascular disease (their father or brother was under 55 or their mother or sister was under 65 when they were diagnosed with cardiovascular disease). * diabetes mellitus. * kidney, liver, pancreas or gastrointestinal diseases. * hematologic disorders (i.e. anaemia; men:haemoglobin\<13.8g/dl (8.56mmol/l) and women\<12.1 g/dl (5.51mmol/l)). * planning a weight reducing regime. * parallel participation in another dietary intervention study.
near to infrared (nir) light neuroprotection in glaucomatous optic neuropathy

Conditions: Open Angle Glaucoma

Summary: the purpose of the study is to evaluate if near-to-infrared light stimulation can improve retinal ganglion cell function in glaucomatous patients.

ganglion cell dysfunction in glaucomatous optic neuropathy has been ascribed to ganglion cell electrophysiological inactivation and to apoptotic cell death. near-to-infrared light stimulation has been used to induce mitochondrial activation and to prevent apoptotic death through mitochondrial cytochrome oxidase c stimulation. near-to-infrared light stimulation might be useful to induce ganglion cell activation and inhibit apoptotic cell death. we propose that near-to-infrared light stimulation can be used as an adjuvant treatment combined with ocular hypotensive treatment in glaucomatous patients.

Eligibility criteria:
inclusion criteria: * clinical diagnose of ocular hypertension (cup to disk ratio 0,6 or less, normal humphrey 24-2 visual field with aplanatic iop over 21 mmhg) or mild glaucoma (cup to disk ratio 0,6 to 0,8, characteristic humphrey 24-2 visual field defect psd between 3 and 6 db). * visual acuity 20/40 or better exclusion criteria: * diabetic retinopathy, multiple sclerosis, parkinson disease * refractive error of 3 diopters or more

Keywords: open angle glaucoma biophotomodulation near to infrared light stimulation neuroprotection
evolution of adipokines and body composition in rheumatoid arthritis patients receiving tocilizumab therapy

Conditions: Arthritis, Rheumatoid

Summary: the aim of this study is to analyze the variation of adiponectinemia and its molecular forms in ra patients receiving tocilizumab therapy.

rheumatoid arthritis (ra) is a chronic inflammatory disease associated with cardiovascular morbidity. tocilizumab (tcz), a monoclonal antibody against the interleukin-6 receptor is an effective new biotherapy for the treatment of ra. this treatment is associated with increased ldl and hdl-cholesterol lipid parameters. adipokines are adipose tissue-specific secreted molecules, which have many functions such as regulation of appetite, blood glucose or immune response. among the adipokines, adiponectin exerts beneficial effects on the cardiovascular system. patients with ra also exhibit body composition changes, including an increase in abdominal visceral fat. the impact of tocilizumab therapy in ra patients on adipokines and body composition is not known. this project aims to explore the evolution of circulating adiponectin and other adipokines during tocilizumab therapy in ra. body composition and its variations under tocilizumab therapy will also be analyzed.

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of ra and requiring tocilizumab therapy * subject has provided written informed consent exclusion criteria: * corticosteroid therapy (10 mg/day of prednisone or equivalent) * pregnant or lactating women * uncontrolled type 1 or type 2 diabetes * uncontrolled dyslipidemia * elevated transaminases (\> three times higher than the normal range) * history of diverticulitis or intestinal perforation * tocilizumab contraindications: severe or active infections, hypersensitivity to the active substance or to any of the excipients

Keywords: adipokines tocilizumab
temporomandibular joint and covid-19

Conditions: COVID-19; Temporomandibular Disorder; ASA Triad

Summary: there is evidence that cv-19 is associated with joint symptoms, but there are no specific data on the temporomandibular joint (tmj). it is also known that the systemic health status can impact the immune system. given all this, this study aimed to investigate the effect of cv-19 and systemic health status, as determined by the american society of anesthesiologists (asa) physical status classification system 12, on tmj in patients with tmj complaints using the dc/tmd scale.

this study investigates the effect of systemic status, according to american society of anesthesiologist (asa), and covid-19 on temporomandibular joint (tmj) disorders using the diagnostic criteria for temporomandibular disorders (dc/tmd) scale, shown to be valid for assessing tmj disorders. the study included 76 patients who presented to our clinic with tmj. participants were divided into two groups: those with covid-19 (cv-19, study group) and those without (non-cv-19, control group). these two groups were both further divided into subgroups according to asa 1 and asa 2 classification. power analyses were performed using g\*power software to determine the required number of patients. groups were compared using the symptom questionnaire, a demographics survey, the graded chronic pain scale (gcps), and the jaw functional limitation scale-20 (jfls-20) of the dc/tmd. the statistical software program version 1.6.23 was used for statistical analysis. although joint complaints were more common in asa 2 patients with cv-19, the groups were not significantly different. the cv-19 asa 2 group had the highest jfls-20 score (mean: 1.3±1.5) and the non-cv-19 asa 1 group had the lowest jfls-20 score (mean: 0.7±0.8), but the differences were again not significant. joint complaints were more common and more severe in asa 2 patients with cv-19, albeit not with statistical significance. more studies are needed to better understand our results.

Eligibility criteria:
inclusion criteria: * applied to our clinic with tmj discomfort * asa 1 and asa 2 patients exclusion criteria: * patients with acute cv-19 * patients who are not in asa 1 or asa 2 classification * patients under 18 year-old * pregnants

Keywords: coronavirus tmj disorder dc/tmd asa sars-cov-2
the whole body vibration for sarcopenic hospitalized patients aged 80+ years

Conditions: Sarcopenia

Summary: resistance training have been recommended for sarcopenic patients. however, the whole body vibration training would further benefit for sarcopenic patients on the basis of resistance training remains unclear. the purpose of this study is to explore the effect of the whole body vibration training on improving the mobility of elderly patients with sarcopenia. the whole body vibration involves different frequencies that can improve muscle strength and keep aged upright, including the legs and core. these kinds of exercises can improve stability and help prevent falls.


Eligibility criteria:
inclusion criteria: * sarcopenia defined by the asia working group of sarcopenia (awgs) * agree to participant this study and sign the informed consent * aged 80 years or over exclusion criteria: * patients who could not follow the training plan due to cognitive impairment, emotional problems or any other reasons; * severe heart and lung diseases; * renal insufficiency; * any type of tumor; * bedridden patients
training of patients with hip fracture

Conditions: Hip Fracture

Summary: the primary purpose of this study is to illustrate whether there is a difference in the 6 minutes walking test in patients with hip fractures who have received 6 vs. 12 weeks of physical training after discharge from hospital.


Eligibility criteria:
inclusion criteria: * patients with hip fractures * full weightbearing on the affected leg * patients living in their own home with an independent walking ability score \>=2 according to the new mobility score scale * written consent exclusion criteria: * institutionalized patients * more than 2 weeks after discharge from hospital * non weight bearing on the affected leg * dementia * other conditions/diagnosis that would have an effect on the ability to train eg. neurological diagnosis

Keywords: lower limb strength training randomized clinical trial patients with hip fracture 6 vs. 12 weeks physical strength training
management of obese patients with gastroesophageal reflux disease .

Conditions: Obesity and Obesity-related Medical Conditions

Summary: the aim of this study is to evaluate the efficacy sleeve gastrectomy with cruroplasty with or without ligamentum teres wrapping for management of morbidly obese patients with concomitant reflux symptoms.

all patients underwent a preoperative work-up including history and physical examination, routine laboratory investigations, ecg, chest radiography, pulmonary function tests, abdominal ultrasonography, and barium swallow, upper git endos¬copy, 24 hours ph monitoring, nutritional, and psychiat¬ric evaluation. further exams and/or consultations were performed when indicated. the study design was a pro¬spective randomized controlled study that received ap¬proval from the ethics committee in relevant hospitals. all the patients gave an informed written consent all patients had a written informed consent of the two types laparoscopic procedures of obesity, prophylactic anticoagulant medications will be given to all patients in the form of subcutaneous clexane 0.5 unit/kg/24. an intensive care unit (icu) bed will be reserved for all patients the night of operation with the decision of transfer left to the postoperative recovery assessment. according to the patient selection, all patients will be divided into two groups as follows: group (a): patients will do laparoscopic sleeve gastrectomy with crural repair. under a general anesthesia, the patient was placed in the split-leg position with the surgeon standing between the legs and the assistant on the left-hand side of the pa¬tient. a veress needle was used to create the pneumoperi-toneum. three 12-mm trocars were inserted in the upper abdomen (one on the right, two on the left side) and one 5-mm trocar was inserted laterally in the left-upper quad¬rant. retractor was inserted through the subxyphoid 10 mm trocar site to re¬tract the liver (five to seven trocars always used) the hiatal hernia sac containing the proximal stomach was reduced. distal esophagus and gastroesophageal junction were mobilized by using a laparoscopic harmon¬ic scalpel (ethicon endo-surgery inc., cincinnati, oh) to get a 4-cm tension-free intra-abdominal esophagus. pos¬terior crural

Eligibility criteria:
inclusion criteria: * age 18-60 years. * both sexes. * bmi ≥ 40 or ≥ 35 with co-morbidity.with reflux symptoms . * failure of non-surgical treatment. * patients with hiatus hernia . * absence of endocrinal or psychological disorders. * failure of non surgical treatment * non sweat eaters * patients with no previous upper git surgeries exclusion criteria: * presence of endocrinal or psychological disorders. * morbidly obese patients with no reflux symptoms * sweat eaters * patients with barrett,s oesophagus , * patient with bad general condition

Keywords: obesity and reflux
chemotherapy and tumor clearance in hepatic resections for colorectal liver metastases.

Conditions: Colorectal Cancer Metastatic; Liver Metastases

Summary: retrospective analysis of a prospectively collected database of 170 patients between 2004 and 2020, who underwent liver resections for crlm (colorectal liver metastases) at the queen elizabeth hospital trying to determine rates and patterns of recurrence following liver resections for crlm and concurrently, characterise clinical, pathological and treatment-related factors that could function as predictors of recurrence or survival, particularly neoadjuvant chemotherapy and tumour clearance.

this is a descriptive, observational study with retrospective analysis of a prospectively collated database. this database included all patients who underwent curative hepatic resections for crlm (colorectal liver metastases) at the queen elizabeth hospital (adelaide, australia) between december 2004 and october 2020.

Eligibility criteria:
inclusion criteria: * patients who underwent a liver resection for crlm at the queen elizabeth hospital between december 2004 to september 2020 exclusion criteria: * patients whose procedures were abandoned due to unresectable tumour burden
environmental pollutants and their effects on respiratory allergy

Conditions: Allergic Rhinitis; Allergic Asthma; Pollution; Exposure

Summary: in latin america and the caribbean, more than 100 million people are exposed to higher levels of pollution than those recommended by who. the objective of the study is to determine the relationship between exposure to environmental pollutants and the prevalence and exacerbation of respiratory allergy. it is an observational, prospective, longitudinal and descriptive study that will include subjects older than 6 years who come to the consultation of the regional center for allergy and clinical immunology with a diagnosis of respiratory allergy, positive skin tests and who live in monterrey and its metropolitan area. after verbal assent, the subject's address and work area will be registered, the rhinitis control assessment test and the asthma control test as well as spirometry will be made. the geolocation of industries and avenues near the address and work area of subjects will be carried out, as well as the determination of pollutants and pollens by the integral monitoring system (sima) and the pollen sense device. subsequently, the correlation between exposure to pollutants and respiratory allergy will be analyzed. dispersion models will be built considering pollutants and climatic factors (precipitation, wind speed, humidity and temperature). by carrying out this project, it will be possible to contribute to the identification of the factors that lead to the development and exacerbation of allergic respiratory diseases and subsequently propose the implementation of measures for their control and recommendations for prevention to the population.


Eligibility criteria:
inclusion criteria: * subjects over 6 years of age who attend the the regional center of allergy and clinical immunology of the university hospital "dr. josé eleuterio gonzález "with a diagnosis of respiratory allergy (allergic rhinitis and asthma) and type i immunological hypersensitivity demonstrated by skin tests by an allergist; and who live in the city of monterrey and its metropolitan area. exclusion criteria: * subjects for whom it is not possible to perform a pulmonary function test or who have concomitant diseases such as copd, heart disease or some other pathology that, in the opinion of the investigator, may cause confusion with respiratory symptoms. patients with negative skin tests to aeroallergens.

Keywords: pollutants allergy symptoms
schlahf-xt-register. sleep disordered breathing in heart failure register

Conditions: Heart Failure (HF)

Summary: the schlahf xt registry is a longitudinal study of patients with heart failure (hf). the study aims to understand the importance of diagnosis and treatment of sleep disordered breathing (sdb) on hf with the following questions: how often does sdb occur in hf? what forms of sdb occur and how are they treated? how does sdb develop over time? how does the heart failure therapy affect sdb? what is the treatment adherence of patients treated? does sbd and its treatment affect the survival of heart failure patients?


Eligibility criteria:
inclusion criteria: * diagnose chronic heart failure, at least 3 months prior to diagnosis * age 18 years * signed informed consent exclusion criteria: * existing positive airway pressure (pap) therapy or long-term oxygen therapy * lack of capacity to consent * minors * persons who are housed on judicial or administrative order in an institution * pregnant and lactating women

Keywords: heart failure chronic heart failure sleep disordered breathing sleep apnea positive airway pressure